Feedback

Pfizer's new antiviral pill 89% effective in high-risk cases

Source : 112 Ukraine

The drug - Paxlovid - is intended for use soon after symptoms develop in people at high risk of severe disease
19:35, 5 November 2021

Reuters

Pfizer has announced that its experimental pill is highly effective at preventing people at high risk of severe Covid-19 from needing hospitalization or dying. It is reported by The New York Times.

An experimental pill  cuts the risk of hospitalisation or death by 89% in vulnerable adults, clinical trial results suggest.

The drug - Paxlovid - is intended for use soon after symptoms develop in people at high risk of severe disease.

News of the antiviral pill comes the same week as Merck announced it had developed an antiviral pill to treat Covid-19 in high-risk patients. According to Merck, the drug was 50% effective in preventing serious illness from the virus.

Related: Sick leave not to be paid during suspension from work due to refusal of vaccination

“These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of Covid-19 infections, and eliminate up to nine out of 10 hospitalizations,” Albert Bourla, chairman CEO of Pfizer, said in a statement.

Meanwhile, Ukraine is hosting clinical tests of pills from coronavirus produced by Pfizer and Merck companies. 

According to the document, one of the drugs to be tested is Ritonavir produced by Pfizer (150 mg). The tests will involve the people who contacted those who contracted Covid-19.

MK4482-013 pills by Merck will be tested as well. Adults who live with Covid-positive people will participate. The lab tests are to take place at the facility of student hospital attached to Kharkiv city council.

 

 

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more